<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751279</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201205</org_study_id>
    <secondary_id>2020-A02330-39</secondary_id>
    <nct_id>NCT04751279</nct_id>
  </id_info>
  <brief_title>Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells</brief_title>
  <acronym>JAK-SARC</acronym>
  <official_title>Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the&#xD;
      clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to&#xD;
      identify the most suitable patients to receive treatment targeting this pathway, in&#xD;
      particular in cases of severe sarcoidosis refractory to the various therapeutic lines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that the JAK/STAT signaling pathway constitutes a new step in&#xD;
      the clinical and therapeutic progress of sarcoidosis, in particular in cases of severe&#xD;
      sarcoidosis refractory to the various therapeutic lines. The main objective of this proposal&#xD;
      is to evaluate the presence and stage of activation of the JAK/STAT pathway in PBMCs from&#xD;
      inactive and active sarcoidosis patients. The second objective will be to determine the role&#xD;
      of the JAK/STAT pathway in the formation and maintenance of granulomas and their association&#xD;
      with the severity of sarcoidosis and fibrogenesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">January 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>JAK/STAT familly numbers protein expression in PBMCs</measure>
    <time_frame>1 year after inclusion</time_frame>
    <description>Evaluation will be carried out by:&#xD;
- studying the expression of members of the JAK/STAT pathway, the expression of cytokines and chemokines phagocytosis and macrophage differentiation the expression of cytokines and chemokines</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>JAK-STAT Pathway Deregulation</condition>
  <arm_group>
    <arm_group_label>Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (&lt;5 years)</arm_group_label>
    <description>Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score &lt;2) and recent diagnosis (&lt;5 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (&lt;5 years</arm_group_label>
    <description>Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (&lt;5 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with pulmonary sarcoidosis without signs of activity , persistent form (&gt;5 years)</arm_group_label>
    <description>Patients with pulmonary sarcoidosis without signs of activity (Benamore score &lt;2), persistent form (&gt;5 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (&gt;5 years)</arm_group_label>
    <description>Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (&gt;5 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml</description>
    <arm_group_label>Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (&gt;5 years)</arm_group_label>
    <arm_group_label>Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (&lt;5 years</arm_group_label>
    <arm_group_label>Patients with pulmonary sarcoidosis without signs of activity , persistent form (&gt;5 years)</arm_group_label>
    <arm_group_label>Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (&lt;5 years)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood mononuclear cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mediastino-pulmonary sarcoidosis receiving or not receiving treatment for&#xD;
        their sarcoidosis. Subjects treated for their sarcoidosis (corticosteroids and/or&#xD;
        immunosuppressants) are not excluded because of two recent cases reported of multi-treated&#xD;
        patients in which an involvement of the JAK/STAT pathway was demonstrated.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS /&#xD;
             ERS / WASOG criteria&#xD;
&#xD;
          -  Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other&#xD;
             probable causal factor identified on the usual standard examination at the time of the&#xD;
             sample with the need for diagnostic confirmation at the end of the study according to&#xD;
             the criteria of the ATS / ERS / WASOG&#xD;
&#xD;
          -  Sarcoidosis with stage 1 to 4 pulmonary involvement&#xD;
&#xD;
          -  Patients who had a chest CT scan in the 6 months preceding the sample. Examination&#xD;
             carried out as part of routine care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Opposition expressed to participation in the study.&#xD;
&#xD;
          -  Patients on State Medical Aid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JENY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence JENY, MD</last_name>
    <phone>0148955129</phone>
    <email>florence.jeny@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie BESNARD, PhD</last_name>
    <email>valerie.besnard@univ-paris13.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de pneumologie Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JENY, DR</last_name>
      <phone>01 48 95 74 35</phone>
      <email>florence.jeny@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Zahia BEN ABDESSELAM, Dr</last_name>
      <phone>01 48 95 74 35</phone>
      <email>zahia.ben-abdesselam@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Florence JENY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018 Dec 20;52(6). pii: 1801482. doi: 10.1183/13993003.01482-2018. Print 2018 Dec.</citation>
    <PMID>30361243</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>JAK/STAT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Granuloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

